目的：观察康柏西普(Conbercept，0.5mg)玻璃体腔注射治疗视网膜中央静脉阻塞继发黄斑水肿的临床疗效和相关并发症。

方法：将2014-10/2015-10临床确诊的48例48眼视网膜中央静脉阻塞继发黄斑水肿患者纳入本研究，患者分为康柏西普组(24例24眼)和对照组(曲安奈德，24例24眼)。对两组患者分别进行玻璃体腔注射治疗，观察指标包括术前和术后1wk，1、3、6、12mo的最佳矫正视力、眼压、玻璃体注射情况、黄斑中心凹视网膜厚度和相关并发症。

结果：两组患者注射前各观察参数对比，均无统计学差异(P>0.05)。两组患者间术后1wk，1、3、6、12mo最佳矫正视力改善情况比较，均无统计学差异(P>0.05)； 术后各时间点黄斑中心凹视网膜厚度与术前相比，康柏西普组分别下降了130.17±1.72、253.33±3.14、318.00±1.41、20.01±1.21、15.09±1.41μm，无注射康柏西普相关并发症发生； 对照组分别下降了132.5±2.07、249.67±1.21、317.50±4.23、18.01±1.41、16.09±1.31μm，无注射曲安奈德相关并发症发生。术后各时间点间比较，两组患者黄斑中心凹视网膜厚度比较，差异均无统计学意义(F=6.882，P=0.663>0.05)； 在注射和观察12mo内，对照组平均注射2.83±0.72次，康柏西普组注射3.17±0.71次，两组在次数上比较差异无统计学意义(P>0.05)； 在并发症和操作过程方面，对照组前房穿刺4眼(17%)，术后高眼压3眼(13%)，经降眼压治疗后眼压控制正常，未出现视神经损害，并发性白内障1眼(4%)，康柏西普组均未发生以上相关并发症。

结论：玻璃体腔注射康柏西普治疗视网膜中央静脉阻塞继发黄斑水肿是一种效果明显、并发症少、安全的治疗方法。

METHODS: According to the selective criteria, from October 2014 to October 2015, 48 cases(48 eyes)of patients with macular edema secondary to CRVO were collected, which were divided randomly into conbercept group(24 cases, 24 eyes)and control group(triamcinolone acetonide 4mg/0.1mL, 24 cases,24 eyes). The best-corrected visual acuity(BCVA), intraocular pressure, intravitreous injection, fundus oculi, central macular thickness(CMT)and related complications were observed before and 1wk, 1, 3, 6 and 12mo after intravitreous injection.

RESULTS: There was no difference on BCVA, intraocular pressure, intravitreous injection, fundus oculi and CMT between the two groups before operations(P>0.05). There were no significant differences(P>0.05)of the BCVA between two groups after treatment for 1wk, 1, 3, 6 and 12mo. Before and after treatment, the decrease of CMT in conbercept group was respectively 130.17±1.72μm, 253.33 ±3.14μm, 318.00±1.41μm, 20.01±1.21μm and 15.09±1.41μm, and no related complications. The decrease of CMT in control group was respectively 132.5±2.07μm, 249.67±1.21μm, 317.50±4.23μm, 18.01±1.41μm and 16.09±1.31μm, and no related complications. There were no significant differences(F=6.882, P=0.663>0.05)of CMT between two groups after treatment for 1wk, 1, 3, 6 and 12mo. Injection times were respectively 2.83±0.72 and 3.17±0.71 in control group and conbercept group, and the difference between two groups has no statistical significance(P>0.05). There were 4 cases(17%)of paracentesis of anterior chamber, 3 cases(13%)of intraocular hypertension and 1 case(4%)of complicated cataract in control group. There was no related complications in conbercept group.

CONCLUSION: Intravitreous injection of conbercept for macular edema secondary to CRVO is effective, safe and less complications.